LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Home・Elenco Azioni・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

24.41 0.54

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

24.41

Massimo

24.41

Metriche Chiave
By Trading Economics
Entrata	675K 53M
Vendite	1.8M 148M
P/E Media del settore	14.228 110.024
Margine di Profitto	35.57
Dipendenti	181
EBITDA	1.7M 80M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+44.03% upside

Dividendi
By Dow Jones
Utili prossimi	25 feb 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	366M 3B
Apertura precedente	23.87
Chiusura precedente	24.41

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

N/A / 24.28 Supporto e resistenza

Catalyst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 feb 2026, 23:55 UTC

Discorsi di Mercato

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

22 feb 2026, 23:53 UTC

Discorsi di Mercato

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

22 feb 2026, 23:53 UTC

Discorsi di Mercato

Key China Rates Likely to Be Held Steady for Now -- Market Talk

22 feb 2026, 23:51 UTC

Discorsi di Mercato

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

22 feb 2026, 23:35 UTC

Discorsi di Mercato

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

22 feb 2026, 23:21 UTC

Utili

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

22 feb 2026, 23:20 UTC

Utili

Nickel Industries 2025 Operating Profit US$126.4 Million

22 feb 2026, 23:19 UTC

Utili

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

22 feb 2026, 23:19 UTC

Utili

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

22 feb 2026, 23:18 UTC

Utili

Nickel Industries Won't Pay a Final Dividend

22 feb 2026, 23:16 UTC

Utili

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

22 feb 2026, 21:35 UTC

Utili

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

22 feb 2026, 21:34 UTC

Utili

Ampol Says F&I Australia, International Have Begun 2026 Strongly

22 feb 2026, 21:34 UTC

Utili

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

22 feb 2026, 21:33 UTC

Utili

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

22 feb 2026, 21:33 UTC

Utili

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

22 feb 2026, 21:28 UTC

Utili

Ampol Final Dividend A$0.60/Share

22 feb 2026, 21:28 UTC

Utili

Ampol FY Revenue A$31.37 Billion, Down 10%

22 feb 2026, 21:28 UTC

Utili

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

22 feb 2026, 21:28 UTC

Utili

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

21 feb 2026, 14:31 UTC

Acquisizioni, Fusioni, Takeovers

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21 feb 2026, 05:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

20 feb 2026, 23:12 UTC

Acquisizioni, Fusioni, Takeovers

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 feb 2026, 22:12 UTC

Utili

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 feb 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

20 feb 2026, 21:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

20 feb 2026, 21:23 UTC

Utili

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 feb 2026, 21:20 UTC

Discorsi di Mercato

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 feb 2026, 21:01 UTC

Acquisizioni, Fusioni, Takeovers

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 feb 2026, 20:38 UTC

Discorsi di Mercato

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Confronto tra pari

Modifica del prezzo

Catalyst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

44.03% in crescita

Previsioni per 12 mesi

Media 35 USD 44.03%

Alto 35 USD

Basso 35 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 1 che hanno fornito valutazioni azionarie a Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

N/A / 24.28Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.